Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Menarini
MedTech
Insilico Medicine, Menarini sign second $500M+ cancer drug deal
Their second exclusive, global in-licensing covers a second small molecule inhibitor, this time targeting what they described as a variety of solid tumors.
Conor Hale
Jan 10, 2025 9:30am
Insilico nabs $500M+ biobucks deal for preclinical cancer asset
Jan 4, 2024 10:00am
Context cuts excess fat to carry biotech into ‘24
Sep 28, 2022 11:00am
As Sanofi's SERD falls, Menarini's advances with EU review
Aug 19, 2022 9:20am
Menarini, chased by 3 Big Pharmas, records breast cancer win
Oct 21, 2021 7:05am
Debiopharm buys ImmunoGen ADC to grow cancer pipeline
May 24, 2017 4:26am